Ropeginterferon Alfa 2b for Early Myelofibrosis

Summary

This is a multi-centre phase 2 open-label prospective study designed to assess the efficacy and safety of ropeg patients with pre-fibrotic primary myelofibrosis or DIPSS low/intermediate-1 risk myelofibrosis after 24 months of treatment.

Timeline

Start

2021-09-01

Primary completion

2025-07-31

Completion

2025-12-31

Publications

• Gill H, Au L, Yim R, Lee P, Li V, Chin L, Zhang Q, Chan PY, Lee CYY, Wu TKY, Leung GMK, Kwong YL. Ropeginterferon alfa-2b for prefibrotic myelofibrosis and lower-risk myelofibrosis requiring cytoreduction. Blood Adv. 2026 Jun 9;10(11):3920-3930. doi: 10.1182/bloodadvances.2026019612.

Drugs

Indications